Pre-increment!Chengyitong: It is estimated that the net profit in 2021 will be 96.62 million yuan to 109 million yuan, a year-on-year increase of 60% to 79.84% _ Oriental Fortune Net

　　Chengyitong(SZ 300430, closing price: 14.23 yuan) Released on the evening of January 17performanceNotice, it is expected to belong to a listed company in 2021shareholderofnet profit96.62 million yuan to 109 million yuan, a year-on-year increase of 60% to 79.84%; the main reason for the change in performance is that in 2021, the company will deepen its main business and vigorously develop two business segments. In the intelligent manufacturing sector, based on the intelligent manufacturing business in the field of biological fermentation, the company has expanded its business to chemical synthesis,traditional Chinese medicineAnd plant extraction, pharmaceutical preparations, intelligent packaging fields, to achieve the coverage of the entire pharmaceutical industry chain, so as to give full play to the advantages of the entire industry chain. During the reporting period, the pharmaceutical manufacturing industry performed well. Benefiting from downstream demand, the intelligent manufacturing business segment was operating steadily. With the combined promotion of advantageous businesses and new businesses, the company’s performance grew.

According to the 2020 annual report,ChengyitongThe main business is pharmaceutical biology, rehabilitationmedical instruments, accounting for 78.19% and 21.81% of revenue respectively.

　　ChengyitongThe general manager and chairman of the board are Liang Kai, male, 53 years old, with a bachelor’s degree.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 91

Original title: Pre-increment! Chengyitong: It is estimated that the net profit in 2021 will be 96.62 million yuan to 109 million yuan, a year-on-year increase of 60% to 79.84%